Received May 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | ENQ205 | — |
full menopause; This is a spontaneous report received from a Consumer or other non HCP. A 50-year-old female patient (not pregnant) received BNT162b2 (BNT162B2 NOS), on 04Mar2021 as dose 01, single (Lot number: ENQ205) at the age of 50 years for covid-19 immunisation. The patient's relevant medical history included: "Perimenopause" (unspecified if ongoing), notes: only about 6 months or so. Concomitant medication(s) included: ZOLOFT. The following information was reported: MENOPAUSE (non-serious) with onset 04Mar2021, outcome "not recovered", described as "full menopause". Therapeutic measures were not taken as a result of menopause. Additional Information: The patient was newly in perimenopause, only about 6 months or so. Once she had the vaccine, she was in full menopause. This was diagnosed by an obgyn. The patient did not receive any other vaccines on the same date as the vaccine. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. The patient had no known allergies. No follow-up attempts are possible.
Medical History/Concurrent Conditions: Perimenopause (only about 6 months or so)
ZOLOFT